Received Feb 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
Nurse calling to state that 3 doses of GARDASIL-9 were administered to a patient after a temperature excursion. No further information was available from the HCP. Consent to contact the physician was provided. No additional AE/PQC. Related AE cases; No adverse event; Information has been received from Business Partner/CRO on 11-Feb-2025. This spontaneous report was received from a/an Other health professional and refers to a(n) patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date, the patient started therapy with Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL),, dose number 1, (lot # and expiration date were not reported). On an unknown date, the patient started therapy with Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL),, dose number 3, (lot # and expiration date were not reported). On an unknown date, the patient started therapy with Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL),, dose number 2, (lot # and expiration date were not reported). The patient started therapy with Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL), for the treatment of Prophylaxis. On an unknown date, the patient experienced Nurse calling to state that 3 doses of GARDASIL-9 were administered to a patient after a temperature excursion. No further information was available from the HCP. Consent to contact the physician was provided. No additional AE/PQC. Related AE cases. On an unknown date, the patient experienced No adverse event. At the reporting time, the outcome of Nurse calling to state that 3 doses of GARDASIL-9 were administered to a patient after a temperature excursion. No further information was available from the HCP. Consent to contact the physician was provided. No additional AE/PQC. Related AE cases and No adverse event was unknown. The action taken with Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine was reported as not applicable.